Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ETNA: Adjuvant Pembrolizumab + Paclitaxel vs Surveillance in Early TNBC with High TILs
NCT06078384Phase 2Recruiting
- Sponsor
- Unicancer
- Start
- Dec 2024
- Primary completion
- Jan 2032
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
A Phase 2 trial of pembrolizumab in triple-negative breast cancer (TNBC), sponsored by Unicancer. Started Dec 2024; status: recruiting.
02
Drugs
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT06078384.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06078384.